US 12,188,021 B2
C5a binding nucleic acids
Kai Hohlig, Berlin (DE); Axel Vater, Berlin (DE); Klaus Buchner, Berlin (DE); Christian Maasch, Berlin (DE); and Sven Klussmann, Berlin (DE)
Assigned to APTARION biotech AG, Berlin (DE)
Filed by APTARION biotech AG, Berlin (DE)
Filed on Nov. 7, 2022, as Appl. No. 17/982,469.
Application 16/819,102 is a division of application No. 15/376,338, filed on Dec. 12, 2016, granted, now 10,590,424, issued on Mar. 17, 2020.
Application 17/982,469 is a continuation of application No. 16/819,102, filed on Mar. 15, 2020, granted, now 11,492,625, issued on Nov. 8, 2022.
Application 15/376,338 is a continuation of application No. 14/371,006, granted, now 9,518,265, issued on Dec. 13, 2016, previously published as PCT/EP2013/000056, filed on Jan. 10, 2013.
Claims priority of application No. 12000106 (EP), filed on Jan. 10, 2012; application No. PCT/EP2012/000089 (WO), filed on Jan. 10, 2012; and application No. 12006960 (EP), filed on Oct. 8, 2012.
Prior Publication US 2024/0384275 A1, Nov. 21, 2024
Int. Cl. C12N 15/115 (2010.01); A61K 31/7088 (2006.01); C07K 14/47 (2006.01)
CPC C12N 15/115 (2013.01) [A61K 31/7088 (2013.01); C07K 14/472 (2013.01); C12N 2310/16 (2013.01); C12N 2310/344 (2013.01); G01N 2333/4716 (2013.01)] 22 Claims
 
1. A method comprising administering to a subject with a fibrotic disease, an inflammatory disease of the skin and/or an autoimmune disease of the skin, a nucleic acid molecule that binds human C5a, wherein the nucleic acid molecule comprises a 5′-terminal nucleotide, a central stretch of nucleotides and a 3′-terminal nucleotide, wherein the central stretch of nucleotides comprises a nucleotide sequence of
5′ AUGn1GGUGKUn2n3RGGGHUGUKGGGn4Gn5CGACGCA 3′ (SEQ ID NO:61), wherein n1 is U or dU, n2 is G or dG, n3 is A or dA, n4 is U or dU, n5 is U or dU, and G, A, U, C, H, K, and R are ribonucleotides, and dU, dG and dA are 2′-deoxyribonucleotides.